Page 127 - 《中国药房》2025年6期
P. 127
品不良反应/事件报告分析[J]. 中国药物应用与监测, gions of Gansu Province[J]. Chin J Diabetes,2025,33
2020,17(4):249-252. (1):8-15.
QIN J J,ZHUANG L,YAO C,et al. Analysis on 233 [17] CHANG L Y,HAO X,YU J,et al. Developing a machine
cases of ADR/ADE associated with SSRIs and SNRIs[J]. learning model for predicting venlafaxine active moiety
Chin J Drug Appl Monit,2020,17(4):249-252. concentration:a retrospective study using real-world evi‐
[ 9 ] 罗轶凡,杨舒,初阳. 模型引导的精准用药在临床血药浓 dence[J]. Int J Clin Pharm,2024,46(4):899-909.
度预测中的应用[J]. 药物评价研究,2023,46(7):1620- [18] 沈黎,李智平. 儿童他克莫司个体化给药模型的研究进
1628. 展[J].中国药房,2025,36(1):124-128.
LUO Y F,YANG S,CHU Y. Application of model- SHEN L,LI Z P. Advances in individualized dosing mo-
informed precision dosing in prediction of serum concen‐ dels of tacrolimus for children[J]. China Pharm,2025,36
tration[J]. Drug Eval Res,2023,46(7):1620-1628. (1):124-128.
[10] 中华医学会精神科分会. CCMD-3中国精神障碍分类与 [19] ASRIAN G,SURI A,RAJAPAKSE C. Machine learning-
诊断标准[M].3 版 . 济南:山东科学技术出版社,2001: based mortality prediction in hip fracture patients using
9-168. biomarkers[J]. J Orthop Res,2024,42(2):395-403.
Psychiatry Branch of Chinese Medical Society. CCMD-3: [20] 肖桃,倪晓佳,黄善情,等. 基于治疗药物监测的氟伏沙
Chinese classification and diagnostic criteria of mental dis- 明血药浓度结果及其影响因素分析[J]. 中国临床药理学
orders[M]. 3rd Edition. Jinan:Shandong Science and 杂志,2021,37(22):3064-3067.
Technology Press,2001:9-168. XIAO T,NI X J,HUANG S Q,et al. Research on the
[11] HIEMKE C,BERGEMANN N,CLEMENT H W,et al. therapeutic drug monitoring and influence factors of flu‐
Consensus guidelines for therapeutic drug monitoring in voxamine [J]. Chin J Clin Pharmacol,2021,37(22):3064-
neuropsychopharmacology:update 2017[J]. Pharmacopsy‐ 3067.
chiatry,2018,51(1):9-62. [21] 梁海,夏茹楠,吴炜,等. 影响文拉法辛血药浓度相关因
[12] 黄志伟,王蕊,余一旻,等. 度洛西汀在中国健康受试者 素的研究进展[J]. 中国医院药学杂志,2023,43(15):
中的群体药代动力学研究[J]. 中国临床药理学杂志, 1758-1762.
2024,40(4):598-602. LIANG H,XIA R N,WU W,et al. Research progress of
HUANG Z W,WANG R,YU Y M,et al. Population phar‐ the influencing factors for blood concentration of vanla‐
macokinetics of duloxetine in Chinese healthy subjects[J]. faxine[J]. Chin J Hosp Pharm,2023,43(15):1758-1762.
Chin J Clin Pharmacol,2024,40(4):598-602. [22] 钟璐莲,陈政,郭媛媛,等. 艾司西酞普兰血药浓度/剂量
[13] 梁海月,杨青军,王姣. 盐酸度洛西汀肠溶胶囊在中国健 比的影响因素研究[J]. 中国医院用药评价与分析,2022,
康受试者体内药代动力学与安全性研究[J]. 天津药学, 22(6):668-671.
2024,36(2):1-4,75. ZHONG L L,CHEN Z,GUO Y Y,et al. Influencing fac‐
LIANG H Y,YANG Q J,WANG J. The pharmacokinetics tors of serum concentration/dose ratio of escitalopram[J].
and safety of enteric-coated duloxetine hydrochloride cap‐ Eval Anal Drug Use Hosp China,2022,22(6):668-671.
sules in healthy Chinese volunteers[J]. Tianjin Pharm, [23] MOLDEN E,SPIGSET O. Interactions between metopro‐
2024,36(2):1-4,75. lol and antidepressants[J]. Tidsskr Nor Laegeforen,2011,
[14] 刘斐烨,凌静,丁可. 基于样本筛选优化的支持向量机预 131(18):1777-1779.
测万古霉素血药浓度[J]. 中国医院药学杂志,2022,42 [24] QIN X,XIE C,HAKENJOS J M,et al. The roles of
(10):1015-1019. CYP1A2 and CYP2D in pharmacokinetic profiles of sero‐
LIU F Y,LING J,DING K. Prediction of vancomycin tonin and norepinephrine reuptake inhibitor duloxetine
serum concentration based on SVM with sample selection and its metabolites in mice[J]. Eur J Pharm Sci,2023,
optimization[J]. Chin J Hosp Pharm,2022,42(10):1015- 181:106358.
1019. [25] 赵婷,李红健,翁振群,等. 基于人工神经网络的新疆维
[15] XUE B,LI D W,LU C Y,et al. Use of machine learning 吾尔族癫痫患儿奥卡西平血清浓度预测研究[J]. 中国药
to develop and evaluate models using preoperative and in‐ 学杂志,2020,55(16):1376-1380.
traoperative data to identify risks of postoperative compli‐ ZHAO T,LI H J,WEN Z Q,et al. Prediction of serum
cations[J]. JAMA Netw Open,2021,4(3):e212240. concentration of oxcarbazepine in Uygur children with
[16] 杨建宁,洪豆豆,李杨,等. 甘肃省不同地区糖尿病肾脏 epilepsy in Xinjiang based on artificial neural network[J].
疾病的机器学习预测模型的研究[J]. 中国糖尿病杂志, Chin Pharm J,2020,55(16):1376-1380.
2025,33(1):8-15. (收稿日期:2024-09-06 修回日期:2025-01-11)
YANG J N,HONG D D,LI Y,et al. Machine learning pre‐ (编辑:舒安琴)
diction model of diabetic kidney disease in different re‐
中国药房 2025年第36卷第6期 China Pharmacy 2025 Vol. 36 No. 6 · 757 ·